US EditionPublished • loading... • Updated
CAT’s remake of Pfizer/Flynn excessive pricing fine is “irrational”, CMA says
Summary by globalcompetitionreview.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CAT’s remake of Pfizer/Flynn excessive pricing fine is “irrational”, CMA says
The UK’s Competition and Markets Authority has claimed the country’s specialist antitrust tribunal mischaracterised its case when annulling reimposed fines on Pfizer and Flynn for allegedly hiking the price of a lifesaving anti-epilepsy drug, an appellate court has heard.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
